A Multi-tasker
Julie Kim, who is currently President of the Plasma-Derived Therapies Business Unit, has been appointed President of the US Business Unit and US country head in 2022. In this role, Julie will focus on continuing to grow Takeda’s business in the US, a key market for the company’s success. Based in the US, Julie joined Takeda in 2019 through the acquisition of Shire, where she held a number of diverse roles such as Global Franchise Head in different therapy areas, international market access, country and regional general management.
“WE NEED TO MAKE SMALL, BUT IMPORTANT, CHANGES IN BEHAVIOUR TO BE INCLUSIVE, NOT JUST WITH OUR COLLEAGUES BUT ALSO PATIENTS, PARTNERS AND OTHER STAKEHOLDERS.”